Biotechnology
BioRes Ruizhi BLC Implant System Showcased in China, Addressing Rising Demand for High-quality Implants
WALNUT, Calif., March 3, 2025 /PRNewswire/ -- BioRes Dentech Inc. showcased its Ruizhi BLC Implant System at Dental South China 2025, a premium product line jointly launched by BioRes Dentech Inc. and Besmile, designed exclusively for China's market. With advanced bone preservation technology and ...
2025-03-03 15:00
1801
CARsgen's Claudin18.2 CAR-T Therapy Satri-cel Granted Breakthrough Therapy Designation by the NMPA
SHANGHAI, March 2, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that the Center for Drug Evaluation (CDE) ofChina's National Medical ...
2025-03-03 08:15
2321
Breakthrough! Exciting interim Phase II Data of LP-003 in CSU released by Longbio at AAAAI 2025
SAN DIEGO, March 2, 2025 /PRNewswire/ -- Longbio Pharma (Suzhou) Co., Ltd. (referred to as "Longbio"), a leading biotech company dedicated to developing innovative biologic treatments for allergy, respiratory, dermatology, hematology, ophthalmology, and other autoimmune and rare diseases, proudly...
2025-03-03 02:00
1843
Bambusa Therapeutics Announces First Subject Dosed in Phase 1 Clinical Trial of BBT001, a Novel Multi-Targeting, Half-Life Extended Bispecific Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Skin Diseases
Preclinical data with BBT001 demonstrate its best-in-disease potential for improved efficacy and dosing convenience compared to approved biologics in atopic dermatitis Interim safety and pharmacokinetic data from healthy volunteers anticipated in 2H 2025 BOSTON, Feb. 28, 2025 /PRNewswire/ -- Ba...
2025-02-28 22:58
4557
Fapon Biopharma Announces FDA Approval of IND for FP008, a First-in-Class Immunotherapy for Solid Tumors
DONGGUAN, China, Feb. 28, 2025 /PRNewswire/ -- Fapon Biopharma, a biotech innovator in developing therapeutic antibodies and fusion proteins, is pleased to announce that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for FP008, its first-in...
2025-02-28 16:39
2102
CARsgen's Allogeneic CD19/CD20 CAR-T Therapy Administers First Dose in a Patient with Autoimmune Disease
SHANGHAI, Feb. 27, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that KJ-C2219, an allogeneic CAR-T therapy targeting CD19/CD20, has a...
2025-02-28 08:15
2413
Ubie and Nucleus Genomics Partner to Enhance Access to Genetic Testing and Drive Early Screening for Improved Health Outcomes
* Genetic testing can be critical to ensuring the early diagnosis and proper treatment of serious disease for patients of all ages * The partnership combines Ubie's AI-driven symptom identification and high rates of patient engagement with Nucleus Genomics' cutting-edge complete DNA sequencin...
2025-02-27 22:30
2558
WuXi Biologics Again Passed GMP Inspection by Japan PMDA
WUXI, China, Feb. 26, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that it has again passed the GMP inspection byJapan's Pharmaceuticals and Medical Devices Agency (PMDA) for it...
2025-02-27 12:30
2265
Lunit Announces Leadership Transition at Volpara: Craig Hadfield Appointed CEO
SEOUL, South Korea and WELLINGTON, New Zealand, Feb. 26, 2025 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced the appointment ofCraig Hadfield as the new CEO of its subsidiary, Volpara Health Technologies. ...
2025-02-26 22:00
2567
Fosun Pharma Received NMPA Approval for Wan Ti Le (Tenapanor Hydrochloride Tablets)
Bringing New Hope to Chinese Dialysis Patients with Hyperphosphatemia SHANGHAI, Feb. 26, 2025 /PRNewswire/ -- Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma; stock code: 600196.SH, 02196.HK) announced that its holding subsidiary, Shanghai Fosun Pharmaceutical Industrial Development...
2025-02-26 18:33
2332
SK bioscience Initiates Global Clinical Trials of mRNA Japanese Encephalitis Vaccine Candidate
* SK bioscience's first mRNA vaccine candidate enters Phase 1/2 clinical trials inAustralia and New Zealand, with interim results expected by 2026 * Joint R&D project between SK and CEPI includes up to USD 40 million in initial funding support from CEPI * SK bioscience will expand its vaccin...
2025-02-25 21:00
2476
CARsgen Therapeutics Introduced Zhuhai SB Xinchuang to Accelerate Allogeneic CAR-T Cell Products Development in Mainland China
SHANGHAI, Feb. 25, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK, "CARsgen Therapeutics"), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces reaching agreements with an investment fund m...
2025-02-25 21:00
2439
WuXi XDC and LigaChem Biosciences Strengthen Partnership with Expanded MOU to Accelerate ADC Development
SHANGHAI, Feb. 25, 2025 /PRNewswire/ -- WuXi XDC Cayman Inc. ("WuXi XDC", or the "Company", stock code: 2268.HK), a leading global CRDMO (Contract Research, Development, and Manufacturing Organization) specializing in antibody-drug conjugates (ADCs) and other bioconjugates, today announced the si...
2025-02-25 18:34
1849
YolTech Therapeutics Announces Positive Clinical Data for YOLT-203, an In Vivo Gene Editing Therapy for Primary Hyperoxaluria Type 1 (PH1)
SHANGHAI, Feb. 25, 2025 /PRNewswire/ -- YolTech Therapeutics, a clinical-stage in vivo gene editing company committed to pioneering the next generation of precision genetic medicines, today reported positive results from the ongoing investigator-initiated trial (IIT) of YOLT-203 in patients with ...
2025-02-25 16:15
1804
BioCity Announces its selective Endothelin Type-A Receptor Antagonist, SC0062, Met the Primary Endpoint in Diabetic Kidney Disease (DKD) in a Phase 2 trial (2-SUCCEED)
SHANGHAI, Feb. 23, 2025 /PRNewswire/ -- BioCity Biopharma (BioCity) announced that its selective endothelin receptor type A (ETA) antagonist, SC0062, met the 12-week primary endpoint of a reduction in proteinuria in the diabetic kidney disease (DKD) cohort of its randomized, double-blind, placebo...
2025-02-25 14:48
4285
CStone Announces Publication of GEMSTONE-303 Study Results for Sugemalimab (Cejemly®) in JAMA
* Sugemalimab is the world's first anti-PD-L1 monoclonal antibody approved for the treatment of gastric or gastroesophageal junction (G/GEJ) adenocarcinoma. The GEMSTONE-303 study results supportsugemalimab in combination with chemotherapy as a new standard first-line treatmentfor patients wit...
2025-02-25 12:10
2321
Akeso Highlights Collaboration Between Its Partner Summit Therapeutics and Pfizer to Explore Ivonescimab in Combination with Pfizer's ADCs
HONG KONG, Feb. 24, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that its partner on ivonescimab, Summit Therapeutics Inc. (NASDAQ: SMMT) has entered into a clinical trial collaboration with Pfizer Inc. (NYSE: PFE) to evaluate ivonescimab, a novel, investi...
2025-02-25 09:13
2029
Visionary Holdings Navigates a New Era of Precision Medicine, Achieving Major Breakthroughs in Targeted Therapy
TORONTO, Feb. 24, 2025 /PRNewswire/ -- In today's era of rapid technological advancement, the deep integration of artificial intelligence and the medical field is bringing unprecedented hope to human health. Among these advancements, targeted therapy, a cornerstone of precision medicine, is gradu...
2025-02-24 22:00
2217
Complete Genomics unveils DNBSEQ-T1+ and DNBSEQ-E25 Flash at AGBT 2025 General Meeting
MARCO ISLAND, Fla., Feb. 24, 2025 /PRNewswire/ -- Complete Genomics, a leading
innovator in genomic sequencing, today unveiled its latest high-performance
sequencing solutions at the 2025Advances in Genome Biology and Technology
(AGBT) General Meeting
2025-02-24 20:00
2092
MGI Tech Closes Strategic Partnership with Oncoclínicas&Co to Contribute to Genomic Innovation in Oncological Health
Agreement contributes to expanding access to cutting-edge genomic technologies and improving diagnostic efficacy SÃO PAULO, Feb. 23, 2025 /PRNewswire/ -- MGI Tech Co., Ltd. ("MGI"), a company committed to building core tools and technologies that drive innovation in life science, established a p...
2025-02-24 11:15
2228
Week's Top Stories
Most Reposted
Amorepacific Showcases Innovative Technologies at CES 2026
[Picked up by 291 media titles]
2026-01-05 12:14
Novo Nordisk International Operations Commits to Veeva Vault CRM
[Picked up by 288 media titles]
2026-01-08 09:05Radisson Hotel Group Revives Bangkok Icon with Opening of Radisson Hotel Chateau de Bangkok
[Picked up by 283 media titles]
2026-01-06 10:45
Courtyard by Marriott Phuket, Patong Beach Resort: The Ultimate Family-Friendly Destination in 2026
[Picked up by 283 media titles]
2026-01-08 12:01
Panduit Announces Key Executive Appointments to Support Strategic Growth and Innovation
[Picked up by 282 media titles]
2026-01-07 10:00
Most Read
Domestic GPU Leader Biren Technology Listed on Hong Kong Stock Exchange
2026-01-02 17:41
7963
The Greatest Meeting The Greatest: Roborock joins hands with Real Madrid in strategic partnership with innovation at the core
2026-01-02 19:00
7493
